Evotec and Takeda collaborate to discover clinical candidates across multiple therapeutic areas
Hamburg-based drug discovery and development company, Evotec (Germany) have entered a new collaboration agreement with Takeda (Tokyo, Japan), Asia’s largest pharmaceutical company.
The announced collaboration agreement is described as a multi-year drug discovery collaboration with a risk sharing, success driven model. The collaboration agreement will see Evotec leading integrated programs, aiming to establish at least five drug discovery campaigns and deliver clinical candidates for Takeda to pursue into clinical development.
Evotec has reportedly received a one-off undisclosed upfront payment from Takeda for access to its platforms. Evotec is also eligible to receive future milestone and tiered royalty payments on future sales.
This is not the first collaboration between Takeda and Evotec explains Steve Hitchcock, Global Head of Research at Takada: “Takeda has a long history of working with Evotec and is confident in Evotec’s capabilities. Collaborating with world-class drug discovery partners like Evotec is central to our model for discovering and developing transformative medicines.”
If successful the collaboration agreement will see Evotec drive fully integrated drug discovery programs in Takeda’s four core therapeutic areas: oncology, gastroenterology, neuroscience and rare diseases with the benefit of strategic insights and development and commercialization expertise from Takeda.
Craig Johnstone, Chief Operating Officer of Evotec concluded: “We believe this collaboration will be very fruitful for both parties and we are excited to combine our resources and skills to produce novel therapies.”
You may also be interested in..
Shimadzu opens new facility in Sweden
Microsampling, automation and instrumentation: an interview with Stephane Moreau
Conference report: opportunities and challenges in translating cell and gene therapy products
